Cargando…

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

BACKGROUND: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsycho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louzã, Mário Rodrigues, Elkis, Helio, Ruschel, Sandra, de Oliveira, Irismar Reis, Bressan, Rodrigo Affonseca, Belmonte-de-Abreu, Paulo, Grabowski, Hamilton, Appolinário, José Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148931/ https://www.ncbi.nlm.nih.gov/pubmed/21822391 http://dx.doi.org/10.2147/NDT.S20589

Ejemplares similares

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
por: Apiquian, Rogelio, et al.
Publicado: (2011)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Singh, Dhiren, et al.
Publicado: (2009)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
por: Catalán, Rosa, et al.
Publicado: (2011)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
por: Williams, Richard, et al.
Publicado: (2014)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

Sertindole in the Management of Schizophrenia
por: Juruena, Mario F., et al.
Publicado: (2011)

Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
por: Olivares, Jose Manuel, et al.
Publicado: (2013)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results
por: Macfadden, Wayne, et al.
Publicado: (2011)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
por: Lambert, Tim, et al.
Publicado: (2011)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

Risperidone Associated Paralytic Ileus in Schizophrenia
por: Ramamourthy, Parthasarathy, et al.
Publicado: (2013)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
por: Haddad, Peter M, et al.
Publicado: (2014)

Medication nonadherence among South American patients with schizophrenia
por: Caqueo-Urízar, Alejandra, et al.
Publicado: (2017)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
por: Asseburg, Christian, et al.
Publicado: (2012)

Neural substrates of cognitive impairment in a NMDAR hypofunction mouse model of schizophrenia and partial rescue by risperidone
por: Delgado-Sallent, Cristina, et al.
Publicado: (2023)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011)

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)
por: Crivera, Concetta, et al.
Publicado: (2011)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz, Wagner F, et al.
Publicado: (2020)

Nonadherence in difficult asthma – facts, myths, and a time to act
por: Lindsay, John T, et al.
Publicado: (2013)

Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
por: Lambert, Tim, et al.
Publicado: (2012)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia
por: Attux, Cecília, et al.
Publicado: (2013)

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review
por: Zhornitsky, Simon, et al.
Publicado: (2012)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
por: Nakamura, Yusuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h7qlgi1gkqlkq1cuv11q4mfeg0